News

Multiple attendees of this year's EnVision Summit share insights into what makes the EnVision Summit an enjoyable experience and a great place to learn.

The considerations for biosimilars in clinical practice are interesting and remain to be determined, according to George A. Williams, MD.

According to the company, the investigational, novel eye drop candidate was assigned a PDUFA goal date of October 22, 2023.

Ophthalmologists see new therapy as having a major impact on how geographic atrophy is treated.

Multiple attendees of this year's EnVision Summit share insights into their presentations.

Sessions offer training in ophthalmic translational research, problem-based learning

In a presentation at the EnVision Summit 2023 in Puerto Rico, Sumayya Ahmad, MD, pointed out that for patients with lower Schirmer’s scores and corneal staining, PRK may be a good choice. If the dry eye can be treated preoperatively and the eye has no staining, surgeons can consider LASIK.

Surgeon notes there is no good solution for ending use of topical medications

Those attending the Asia-Pacific Academy of Ophthalmology congress In Kuala Lumpur can celebrate the reconvening of the congress after a 2-year hiatus by joining in the “We Are Back” Fundraising Run.

Having the best tools available is of the utmost importance in the operating room (OR).

At the EnVision Summit Ophthalmology in Puerto Rico, Grace Sun, MD, made a presentation titled "Surgical Curriculum for Ophthalmology Residents" to train them to be competent in a broad range of basic and advanced surgical skills.

At the EnVision Summit Ophthalmology 2023 in Puerto Rico, Eva Kim, MD, made a presentation titled "ICL and Clear Lens Exchange: Choosing the Right Approach."

Corneal neurotization is an efficacious procedure to restore sensation to a neurotrophic cornea, involving the surgical transfer of sensory nerve fibers to the cornea.

During the EnVision Summit Ophthalmology in Puerto Rico, Victor Villegas, MD, made a presentation titled "From a Retina Perspective: Comanagement of AMD, DME and CME in the Setting of Cataract Surgery," focusing on how to comanage patients that have macular degeneration, diabetic maculopathy and cystoid macular edema.

David Huang, MD, PhD, is recognized as a co-creator of a widely used medical imaging technology.

Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD. This news follows the submission of the 24-month phase 3 data in November 2022.

According to the company, the app features new content, including podcasts, discussion forums and downloadable content for eyecare professionals.

During a presentation at the EnVision Summit Ophthalmology 2023 at El Conquistador Resort in Puerto Rico, Elena Bitrian, MD, outlines the challenges that surgeons are confronted with surgically in pediatric eyes, including the limited working space and palpebral fissure, axial length, and avoidance of the thin sclera and shallow scleral pass.

The company announced a PDUFA goal date of Aug. 19, 2023. The FDA has not identified any potential review issues and is not currently planning to hold an Advisory Committee meeting for avacincaptad pegol.

Managing dry eye requires addressing underlying disease process with therapy, treatments

Three of Frontera’s gene therapy product candidates have entered clinical trials since the beginning of the year.

According to a news release, Akari is targeting an Investigational New Drug application submission to the FDA in the first half of 2024.

This marks the first, in-person APAO congress since the COVID-19 pandemic

The collaboration may provide insights to help improve the treatment paradigm for retinal disorders.

The survey addressed topics that would facilitate a better understanding of the awareness of retina specialists regarding this relative new form of treatment in ophthalmology.

According to the company, the formulations do not contain preservatives or boric acid and have a physiologic pH of 5.5. They also can be stored at room temperature for up to 180 days.

Saunders will return to Bausch + Lomb after having served at the company as CEO from 2010 to 2013.

According to the companies, the collaboration will combine Formosa's APNT nanoparticle formulation platform with Eyenovia's Optejet dispensing technology for the development of new ophthalmic therapies in indications with significant unmet medical needs.